All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Response to Letter to the editor: Post-vaccination immunogenicity of BNT162b2 SARS-CoV-2 vaccine and its predictors in pediatric inflammatory bowel disease

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10457969" target="_blank" >RIV/00064203:_____/23:10457969 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/23:10457969

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Hvv-COMPtF" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Hvv-COMPtF</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1097/MPG.0000000000003760" target="_blank" >10.1097/MPG.0000000000003760</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Response to Letter to the editor: Post-vaccination immunogenicity of BNT162b2 SARS-CoV-2 vaccine and its predictors in pediatric inflammatory bowel disease

  • Original language description

    On behalf of our research team, I would like to submit a short response to the Letter to the Editor (&quot;Postvaccination Immunogenicity of COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease.: Comment&quot;) concerning our original article published in JPGN named &quot;Post-Vaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.&quot;We have read with interest the letter submitted by Amnuay Kleebayoon and Viroj Wiwanitkit.(1) In this letter, the authors raise the point that higher post-vaccination levels of anti-spike S2 antibodies in inflammatory bowel disease patients compared to controls could be explained by cross-contamination with &quot;silent COVID-19 infection&quot; in some of the subjects who had no apparent clinical signs at the time of testing.Although this may theoretically be one plausible explanation that we would not be able to rule out (as we did not test all our subjects for SARS-CoV-2 infection along with post-vaccination antibodies), from a statistical point of view we deem unlikely that a silent SARS-CoV-2 infection would appear with different frequency (probability) in each group. Therefore, we consider this unlikely to be a true major factor underlying the difference in the antibody production between inflammatory bowel disease patients and healthy controls. We remain, however, in agreement that the possibility of a cross-contamination with undiagnosed SARS-CoV-2 infections cannot be formally ruled out.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30209 - Paediatrics

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Pediatric Gastroenterology &amp; Nutrition

  • ISSN

    0277-2116

  • e-ISSN

    1536-4801

  • Volume of the periodical

    76

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    1

  • Pages from-to

    "e90"

  • UT code for WoS article

    000992435200006

  • EID of the result in the Scopus database

    2-s2.0-85159770707